VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CLLS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CLLSCellectis S.A.
$1.03$103M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
CLLS logo

Cellectis S.A.

CLLS
NASDAQ · Cell & Gene Therapy
$1.03
At close - Nov 18, 4:00 PM EST - USD
Market Cap$103M
P/E-1.6x
52W High$5.45
Volume6.02K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q1

Milestone Dependency Masks Persistent Clinical Cash Burn

Cellectis remains a high-risk, clinical-stage biotechnology firm whose financial stability is tethered to volatile, non-recurring milestone payments rather than a sustainable commercial revenue model.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

CLLS price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-104% Peers

P/E is 104% below peer median

03

Market leadership

RS 6 · Lag

Laggard (Underperforming 94% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 12

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
CLLS-78.54%
S&P 500 (^GSPC)+6.88%
1-Year Return
CLLS-74.94%
S&P 500 (^GSPC)+10.62%
3-Year Return
CLLS-66.77%
S&P 500 (^GSPC)+52.68%
5-Year Return
CLLS-88.68%
S&P 500 (^GSPC)+56.18%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$73M+75.8% YoY
Net income FY25
-$68M-83.9% YoY
Free cash flow FY25
-$43M-317.7% YoY
Operating margin FY25
-45.3%+98.1 pts YoY
ROIC (FY25)-23.5%
Avg ROIC 5Y-60.5%
ROE (TTM)-94.2%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
Revenue Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 12, 2026
-$0.61-238.9%
vs -$0.18
$4M-75.9%
vs $16M
Q3 2026
Aug 6, 2026
-$0.22+16.3%
vs -$0.26
$7M-37.5%
vs $11M
Q2 2026
May 11, 2026
-$0.18+30.3%
vs -$0.26
$8M-31.6%
vs $11M
Q2 2026
Mar 19, 2026
-$0.26-27.9%
vs -$0.20
$12M-8.9%
vs $13M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·5d ago
Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript

Cellectis S.A. (CLLS) Q3 2026 Earnings Call Transcript

MarketBeat·5d ago
What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis NASDAQ: CLLS said its cash runway is expected to extend into the second half of 2028 once its planned restructuring is fully implemented, giving the gene editing company time to reach anticipated initial clinical readouts for its two lead programs.

Globe News Wire·6d ago
Cellectis publie ses résultats financiers du troisième trimestre 2026 et une mise à jour de ses activités

HEAL-101 a atteint jusqu'à 70 % d'édition in vivo d'APOC3, avec une activité limitée au foie, et a confirmé une réduction de 76 % des triglycérides dans des modèles murins (ESGCT 2026); lancement de l'essai de phase 1 IIT en Chine dans les temps, avec des données cliniques préliminaires attendues au second semestre 2027.

GlobeNewsWire·6d ago
Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update

NEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a genome engineering company developing genetic medicines for diseases that today demand a lifetime of treatment, today reported financial results for the third quarter 2026 ended September 30, 2026, and provided a business update.

Filtered for Cellectis S.A.More Headlines
04

Compare before deciding

Benchmark CLLS against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Cellectis S.A. (CLLS)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CLLS logoCLLSCellectis S.A.Current
$1.03$103.43M-1.5975.76%-115.48%-94.24%—
CRSP logoCRSPCRISPR Therapeutics AG
$40.19$3.88B-8.52-89.97%-1812.07%-25.59%—
BEAM logoBEAMBeam Therapeutics Inc.
$21.01$2.16B-20.54120.01%-73.04%-9.69%—
EDIT logoEDITEditas Medicine, Inc.
$1.77$271.63M-3.7625.39%-144.95%-130.43%—
NTLA logoNTLAIntellia Therapeutics, Inc.
$9.77$1.1B-3.2116.92%-805.75%-64.73%—
FATE logoFATEFate Therapeutics, Inc.
$1.05$122.39M-1.04-51.24%-2619.64%-73.92%—

Compare CLLS vs Peers

Cellectis S.A. (CLLS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CRSP

Most directly comparable listed peer for CLLS.

Scale Benchmark

vs TMO

Larger-name benchmark to compare CLLS against a more recognizable public peer.

Peer Set

Compare Top 5

vs CRSP, BEAM, EDIT, NTLA

Get notified when CLLS posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CLLS Frequently Asked Questions

Cellectis S.A. (CLLS) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Cellectis S.A.'s revenue?

Cellectis S.A. (CLLS) reported $56.6M in revenue over the trailing twelve months. Revenue was $72.9M in fiscal year 2025. That is 1679% more than the $4.1M of fiscal year 2007.

How fast is Cellectis S.A. growing?

Cellectis S.A. (CLLS) grew revenue by 0.5% over the trailing twelve months, compared with the twelve months before.

Is CLLS profitable?

No. Cellectis S.A. (CLLS) reported a net loss of $65.3M over the trailing twelve months.

Dividend & Returns
What is CLLS's return on equity?

Cellectis S.A. (CLLS) had a return on equity (ROE) of -94.2% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is Cellectis S.A.'s free cash flow?

Cellectis S.A. (CLLS) had negative free cash flow of $44.1M over the trailing twelve months.

What if you invested $1,000 in CLLS back in 2007?

Total return calculator · dividends reinvested · 19+ years of data

See returns →